DBV Technologies to Participate in Upcoming ACAAI 2024 Congress
October 18 2024 - 3:30PM
Châtillon, France, October 18, 2024
DBV Technologies to Participate in Upcoming
ACAAI 2024 Congress
DBV Technologies (Euronext: DBV – ISIN:
FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage
biopharmaceutical company, today announced upcoming participation
at the American College of Allergy, Asthma & Immunology (ACAAI)
Annual Scientific Meeting, October 24 – 28th, 2024 in Boston,
Massachusetts.
This year’s meeting will feature a “Product
Theater” on What Defines an Optimal Peanut Allergy Treatment?
During this panel discussion, Drs. Shahzad Mustafa, Edwin Kim,
Julia Upton, and CEO of Food Allergy Research and Education
(FAACT), Eleanor Garrow-Holding will engage in a discussion around
hallmarks of an optimal treatment for peanut allergy, focusing on
the goals of efficacy, safety, and practicality. The Product
Theater is scheduled for Saturday, October 26th, from 11:35 a.m. to
1:00 p.m. EDT.
DBV is also sponsoring the 33rd Annual FIT Bowl,
a game show-type competition that tests allergy, asthma, and
immunology knowledge of participating teams from training programs
around the country. The competition is set to be held on Saturday,
October 26th, from 5:45 p.m. to 7:45 p.m. EDT. In addition, DBV is
a 2024 ACAAI Benefactor Level Corporate Council Member. The Company
will also host a booth in the ACAAI Exhibit Hall from Friday,
October 25th – Monday, October 28th.
“We are very pleased to join our peers in food
allergy at ACAAI again this year, particularly after recently
completing enrollment for VITESSE in children 4 – 7 years old,”
said Dr. Pharis Mohideen, Chief Medical Officer of DBV
Technologies. “Our global collaboration enabled us to
reach this critical milestone. DBV continues to advance our
regulatory progress with the Viaskin® peanut patch in 1 –
3-year-olds and 4 – 7-year-olds. We look forward to opportunities
at the ACAAI to further discuss the unmet medical need in peanut
allergy and explore ways we can work together across the community
to support developments in food allergy.”
DBV Presentation:
Product Theater
(non-CME)“What Defines an Optimal Peanut Allergy
Treatment?” featuring participation from Dr. Shahzad
Mustafa, Rochester Regional Health, Dr. Edwin Kim, UNC Pediatric
Allergy & Immunology, Dr. Julia Upton, MPH, The Hospital for
Sick Children and Eleanor Garrow-Holding, CEO of Food Allergy and
Anaphylaxis Connection Team (FAACT).
- Presentation Date: Saturday,
October 26th
- Presentation Time: 11:35 a.m. to
1:00 p.m. EDT
- Session/location: HCC, Level 2,
Exhibit Halls C & D, Product Theater #2
The Viaskin® Peanut patch is the Company’s lead
product candidate designed to reduce the risk of allergic reactions
due to accidental exposure to peanuts. An investigational,
non-invasive, once-daily epicutaneous patch, the Viaskin Peanut
patch seeks to deliver microgram quantities of peanut antigen to
re-educate the immune system. The safety and efficacy of the
Viaskin Peanut patch have not yet been established by the U.S. Food
and Drug Administration or the European Medicines Agency.
About DBV TechnologiesDBV
Technologies is a clinical-stage biopharmaceutical company
developing treatment options for food allergies and other
immunologic conditions with significant unmet medical need. DBV is
currently focused on investigating the use of its proprietary
Viaskin® patch technology to address food allergies, which are
caused by a hypersensitive immune reaction and characterized by a
range of symptoms varying in severity from mild to life-threatening
anaphylaxis. Millions of people live with food allergies, including
young children. Through epicutaneous immunotherapy (EPIT™), the
Viaskin® patch is designed to introduce microgram amounts of a
biologically active compound to the immune system through intact
skin. EPIT is a new class of non-invasive treatment that seeks to
modify an individual’s underlying allergy by re-educating the
immune system to become desensitized to allergen by leveraging the
skin’s immune tolerizing properties. DBV is committed to
transforming the care of food allergic people. The Company’s food
allergy programs include ongoing clinical trials of Viaskin Peanut
in peanut allergic toddlers (1 through 3 years of age) and children
(4 through 7 years of age).
DBV Technologies is headquartered in Châtillon,
France, with North American operations in Warren, NJ. The Company’s
ordinary shares are traded on segment B of Euronext Paris (Ticker:
DBV, ISIN code: FR0010417345) and the Company’s ADSs (each
representing one ordinary share) are traded on the Nasdaq Capital
Select Market (Ticker: DBVT).
For more information, please visit
www.dbv-technologies.com and engage with us on X (formerly Twitter)
and LinkedIn.
Forward Looking StatementsThis
press release may contain forward-looking statements and estimates,
including statements regarding DBV’s financial condition, forecast
of its cash runway, the therapeutic potential of Viaskin® Peanut
patch and EPIT™, designs of DBV’s anticipated clinical trials,
DBV’s planned regulatory and clinical efforts including timing and
results of communications with regulatory agencies, the ability of
any of DBV’s product candidates, if approved, to improve the lives
of patients with food allergies. These forward-looking statements
and estimates are not promises or guarantees and involve
substantial risks and uncertainties. At this stage, DBV’s product
candidates have not been authorized for sale in any country. Among
the factors that could cause actual results to differ materially
from those described or projected herein include uncertainties
associated generally with research and development, clinical trials
and related regulatory reviews and approvals, and DBV’s ability to
successfully execute on its budget discipline measures. A further
list and description of risks and uncertainties that could cause
actual results to differ materially from those set forth in the
forward-looking statements in this press release can be found in
DBV’s regulatory filings with the French Autorité des Marchés
Financiers (“AMF”), DBV’s filings and reports with the U.S.
Securities and Exchange Commission (“SEC”), including in DBV’s
Annual Report on Form 10-K for the year ended December 31, 2023,
filed with the SEC on March 7, 2024, and future filings and reports
made with the AMF and SEC by DBV. Existing and prospective
investors are cautioned not to place undue reliance on these
forward-looking statements and estimates, which speak only as of
the date hereof. Other than as required by applicable law, DBV
Technologies undertakes no obligation to update or revise the
information contained in this Press Release.
Viaskin is a registered trademark and EPIT is a
trademark of DBV Technologies.
Investor Contact Katie
Matthews+ 1 (857) 529-2363katie.matthews@dbv-technologies.com
Media ContactAngela
Marcucci+1 646-842-2393angela.marcucci@dbv-technologies.com
DBV Technologies (EU:DBV)
Historical Stock Chart
From Oct 2024 to Nov 2024
DBV Technologies (EU:DBV)
Historical Stock Chart
From Nov 2023 to Nov 2024
